|Reticulose||UCDA||Pentoxifylline||Immune therapy||Silymarin||Other herbs||Pegasys|
|Other options for treating HCV|
A new study published in the fall issue of American Journal of Gastroenterology, Vol 89, No. 7, suggests that using "Iron Reduction Therapy" along with interferon can result in an effective cure rate in the area of 75-80% and that adding cytokines and antivirals such as ribavirin can improve effectiveness even further. The theory behind this is that viruses need iron to replicate, and by reducing the hepatic iron in the liver you prevent them from replicating. It should be noted that this new procedure is not yet FDA approved and is still in the early trial stages.
Effects of Phlebotomy in Interferon Non-Responders
Effect of liver iron content on hepatitic inflammation
Many hepatitis C patients show a clear-cut biochemical response to ribavirin, with a lowering of liver enzyme levels. However, the ribavirin does not clear circulating hepatitis C virus RNA and relapses occur after they discontinue taking the drug.
Side-Effects of Ribavirin Observed in HCV Patients
Ribaviron Causes Increase of Hepatic Iron
INTERFERON AND RIBAVIRIN - COMBINED
Clinical trials have completed for a combination drug of interferon-alpha and ribavirin (named REBATRON), and the FDA has approved the use of the drug.
Click here for the results of recent studies using this combination.
Pegasys: Regimen suppresses Hep C
Anti-Oxidant vitamins delay anemia in combo treatment
Amantadine (trade name Symmetrel) is a drug commonly used in the treatment of Parkinson's disease, and for the prophylaxis and treatment of illness caused by the influenza A virus. It is thought to prevent viral uncoating and thus viral multiplication. Amantidine was recently tested in patients with HCV, and clinical trials will be beginning soon.
( From the 96th annual meeting of the American
Gastroenterological Association, Digestive Disease Week , San
Francisco, CA, May 21, 1996)
Dr. J.P. Smith presented the results of a recent trial of the
antiviral agent, amantadine hydrochloride, in patients with chronic
hepatitis C infection who had previously failed to respond to
interferon alpha-2b. Twenty-two patients were treated with orally
administered amantadine HCl, 100 mg twice a day, for 6 months.
These same patients served as their own controls during two
intervals of no treatment (24 months before and 12 months after
previous treatment with interferon) and during interferon therapy.
Twenty of the 22 patients completed the 6-month study of
Thirty percent of those patients completing the study
demonstrated a complete response to therapy as demonstrated by the
normalization of serum alanine aminotransferase (ALT) levels. Forty
percent of the patients achieved a partial response (defined as a
reduction in ALT of greater than 50%), and 30% failed to respond to
amantadine therapy. Responders and partial responders maintained
therapeutic benefits 6 months after treatment was stopped.
Two patients were discontinued from the study as a precaution
due to cardiac-related side effects. Two patients reported
difficulty concentrating, two patients reported constipation, and
one experienced insomnia, but none of these patients discontinued
the study. There was no observed decrease in WBC levels, nor was
there any detrimental effect on the bone marrow attributable to
treatment with amantadine.
Dr. Smith noted that the comparative costs of therapy at the
Hershey Medical Center were $120 for 6 months of therapy with
amantadine HCl vs $3,000 for interferon.
As shown by this study in 20 patients, amantadine HCl (which has
the additional benefit of being taken orally vs by subcutaneous
injection for interferon) may prove to be a useful alternative to
interferon in treating patients with chronic hepatitis C.
"Treatment of Chronic Hepatitis C with Amantadine", J. P. Smith,
The M. S. Hershey Medical Center, Pennsylvania State University
Rimantadine: A Clinical Perspective
Adverse reactions to Amantadine
Amantadine and Rimantadine Have no Effect on HCV
On the basis of the recent report on the antiviral effects of ofloxacin (OFLX) which is antibacterial drug, a study was designed to test the efficacy of OFLX in combination with IFN by a open clinical trial method. Analysis of HCV-RNA titer revealed that it decreased markedly after the beginning of combination therapy. HCV-RNA titer became negative in 8 cases of 11, and in 1 of 8 patients HCV disappeared by OFLX. However, the effects of OFLX were not monitored by HCV-RNA titers. ALT normalised rate at the end of the study in group I and group III (control) were 87.5% and 69.0% respectively, which differences were not statistically significant. The results of the trial indicate that the combination therapy of interferon and ofloxacin may be a possible strategy for the treatment of type C hepatitis.
"Combination therapy of interferon and ofloxacin in patients with chronic type C hepatitis", Takada N.; Yamazaki Y.; Sato T.; Furukawa T.; Matsuzaki H.; Shimada K.; Iwasaki K.; Furube M.; Tomioka H., Japanese Pharmacology and Therapeutics (Japan), 1995, 23/SUPPL. 3
Also read Combination Therapy with Interferon and Ofloxacin
Thymosin alpha 1 is a protein produced by the human body, the cow and others which is supposed to enhance the immune system. It is associated with the thymus gland, which shrinks as we get older - yet has important role in immunity. There are over the counter products which take raw cow thymus - dry - defat - and process the gland in tablet form which some claim when taken causes the human body to increase natural production of "thymosin alpha 1". Dr. Burgstiner in Savannha, Georgia, believes he cured himself of Hep B by using this formula (Telephone 912-355-5755 (ask for Pat)). That preparation is called "Thymic Fractions" and is produced by a company in California called Bio-Naturals at 800-991-7990. The reference to Dr. Burgstiner can be found in Naomi Judd's book " Love Can Build A Bridge" paperback edition - Pages (480-482) Dr. Burgstiner believes that this preparation must be taken with vitamins to act as coenzymes in order to be effective.
There is also a synthetic "thymosin alpha 1" being produced by a
company called SciClone Pharmaceuticals - Telephone - 415-358-1446
available only in trials - It is given intravenously and has been -
and is currently being studied for use in treating Hep B and C - in
Hep B the results have been promising - and it is now being studied
in combination with interferon.
Factors Comments and questions answered by Dr.
Study of Complete Thymic Formula for HCV
U.S. Hepatitis C Trial Statistically Significant
Strong Results In Hepatitis C Trial Using ZADAXIN
Study Data on Zadaxin and Interferon
(Information provided by Commonwealth Pharmaceuticals,
British West Indies, manufacturers of Reticulose) Patients with
Hepatitis A and 18 patients with Hepatitis B were treated with
Reticulose. 9 Patients with Hepatitis A and 17 patients with
Hepatitis B were controls and treated with placebo. The treated
patients received Reticulose for a 15 day period, while the control
received saline. Based upon laboratory findings of several
parameters: Prothrombin times, Serum bilirubin, white blood cell
count, and clinical observations, Reticulose treated patients
appeared to show significant improvement. The bilirubin levels of
83% of patients with Hepatitis B, treated with Reticulose for 15
days were in the normal range in 30 days. None of the control
patients treated with placebo were within normal range in 30 days.
Of Hepatitis A patients treated with Reticulose, 100% showed normal
bilirubin after 30 days. Of control patients with Hepatitis A, only
22% were in normal range after 30 days. The findings in this
preliminary trial lead to the conclusion that Reticulose appears to
significantly reduce the recovery time and return to normal for
patients with an acute episode of Hepatitis A or B. Further study
Conclusions: In this preliminary Human Clinical Trial in 53
patients with Hepatitis A or Hepatitis B, one half of whom were
treated with Reticulose, the results demonstrated positive clinical
and laboratory effects. 18 patients with Hepatitis B and 9 with
Hepatitis A were treated with Reticulose, compared to 17 control
patients with Hepatitis B and 9 control patients with Hepatitis A
treated with placebo. Patients were diagnosed for Hepatitis A or B
by appropriate laboratory tests of blood, urine, x-ray and physical
examination, with special attention to Anti-HAV IGM and HepB
surface Antigen to carefully differentiate those with A from those
with B. We realize, however, that liver biopsy is the positive
method for hepatitis diagnosis, but physical limitations prevented
our using this method in this study. Based upon laboratory
findings, serum bilirubin levels of 83% patients with Hepatitis B,
treated with Reticulose for 15 days were in normal range in 30
days, 50% in 15 days, and 22% in 10 days. None of the control
patients were in normal range after 30 days with placebo treatment.
In the Hepatitis A patients treated with Reticulose, 100% showed
normal bilirubin levels after 30 days, 89% after 15 days, and 33%
after 10 days. In the control patients with Hepatitis A only 22%
were in normal range after 30 days, 11% after 15 days, and 11%
after 10 days. In all of the Reticulose treated patients, the white
blood cell count showed significant increase, indicating stimulus
to the immune system. In all of the Reticulose treated patients,
the prothrombin times returned promptly to normal range while the
controls did not. The results appear to demonstrate significant
improvement in the patients treated with Reticulose, especially
those with Hepatitis B.
The use of Reticulose in the Treatment of Hepatitis A, B & C, Excerpted from: Journal of the Royal Society of Health Volume 112, No. 6, pages 266-270 December, 1992
UCDA descreases the LFTs of chronic liver disease patients treated with SNMC
Ursodeoxycholic acid (UCDA) in the treatment of liver diseases
Combination Ursodeoxycholic Acid and Interferon
PENTOXIFYLLINE enhances response of chronic hepatitis C to INTERFERON [alpha]2b
Immunosuppressive therapy and hepatitis C virus
Sylimarin and other herbs
List of Herbs Used to Treat HCV
Milk Thistle and Licorice in the Therapy of Liver Disease
Study on treating HCV with glycyrrhizin (licorice)
Silymarin complex for liver disorders
Immune stimulating herbs
Alternative medicines for treating HCV
Tips on Supplement Safety
NAC Info Sheet
Phyllanthus Fraternus - A Plant with Anti-Hepatitis Viral Activity
Complementary and Alternative Medicine : Separating the Wheat from the Chaff
What You Should Know Before Trying Herbs
Other options for treating
combination therapy for HCV
Preliminary Results with Nabi Hepatitis C Drug in Chimpanzees
Alternative medicines for treating HCV
Life Extension Foundation's Protocol for HCV